Oral Cancer Drugs Deserve Parity



Oral cancer drugs account for 25% to 35% of the drugs in the cancer drug pipeline. But their high costs are causing some cancer patients to avoid them. It's time for health plans to treat these drugs like injectable cancer-fighting medications.


Name:
E-mail:
Website:  
Please enter your comment below:
Please enter the text below:

SIGN UP

FREE e-Newsletters Join the Council Subscribe to HL magazine

SPONSORSHIP & ADVERTISING

100 Winners Circle Suite 300
Brentwood, TN 37027

800-727-5257

About | Advertise | Terms of Use | Privacy Policy | Reprints/Permissions | Contact
© HealthLeaders Media 2014 a division of BLR All rights reserved.